Delia Alvarez

432 total citations
25 papers, 350 citations indexed

About

Delia Alvarez is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Delia Alvarez has authored 25 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Delia Alvarez's work include Angiogenesis and VEGF in Cancer (6 papers), Vascular Tumors and Angiosarcomas (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Delia Alvarez is often cited by papers focused on Angiogenesis and VEGF in Cancer (6 papers), Vascular Tumors and Angiosarcomas (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Delia Alvarez collaborates with scholars based in United States, Italy and France. Delia Alvarez's co-authors include Charles P. Theuer, Bonne J. Adams, Ben K. Seon, David S. Mendelson, Lee S. Rosen, Jonathan W. Goldman, William D. Figg, Michael S. Gordon, Herbert I. Hurwitz and Michael K. Wong and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Delia Alvarez

25 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Delia Alvarez United States	7	172	124	96	80	27	25	350
Shike Wang China	9	192 1.1×	159 1.3×	43 0.4×	66 0.8×	24 0.9×	13	403
Daniel Karl United States	12	351 2.0×	135 1.1×	102 1.1×	68 0.8×	25 0.9×	19	597
Judit Pápay Hungary	12	139 0.8×	135 1.1×	129 1.3×	90 1.1×	26 1.0×	31	338
Ziyang Liu China	10	185 1.1×	105 0.8×	109 1.1×	130 1.6×	27 1.0×	32	437
Mai Tomiguchi Japan	12	280 1.6×	146 1.2×	80 0.8×	272 3.4×	37 1.4×	24	490
Saumyadipta Pyne United States	5	128 0.7×	198 1.6×	59 0.6×	75 0.9×	13 0.5×	11	357
Montserrat Arumí-Uría Spain	9	252 1.5×	235 1.9×	82 0.9×	101 1.3×	12 0.4×	13	498
Daiki Taniyama Japan	14	277 1.6×	267 2.2×	108 1.1×	123 1.5×	24 0.9×	46	527
D. Grabau Denmark	9	217 1.3×	140 1.1×	60 0.6×	167 2.1×	45 1.7×	11	371

Countries citing papers authored by Delia Alvarez

Since Specialization

Citations

This map shows the geographic impact of Delia Alvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delia Alvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delia Alvarez more than expected).

Fields of papers citing papers by Delia Alvarez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delia Alvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delia Alvarez. The network helps show where Delia Alvarez may publish in the future.

Co-authorship network of co-authors of Delia Alvarez

This figure shows the co-authorship network connecting the top 25 collaborators of Delia Alvarez. A scholar is included among the top collaborators of Delia Alvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delia Alvarez. Delia Alvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Percent, Ivor, Craig H. Reynolds, Kartik Konduri, et al.. (2020). Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).. Journal of Clinical Oncology. 38(15_suppl). TPS9635–TPS9635. 12 indexed citations

Doshi, Gurjyot K., Nicholas J. Vogelzang, Donald Richards, et al.. (2019). Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).. Journal of Clinical Oncology. 37(7_suppl). TPS498–TPS498. 4 indexed citations

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2018). Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Molecular Cancer Therapeutics. 17(10). 2248–2256. 15 indexed citations

Ravi, Vinod, Andrew S. Brohl, Sant P. Chawla, et al.. (2018). Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. Journal of Clinical Oncology. 36(15_suppl). e23570–e23570. 1 indexed citations

Ravi, Vinod, Andrew S. Brohl, Sant P. Chawla, et al.. (2018). TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. Journal of Clinical Oncology. 36(15_suppl). TPS11590–TPS11590. 1 indexed citations

Liu, Yingmiao, Zhenhua Yuan, Dadong Zhang, et al.. (2017). Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. Journal of Clinical Oncology. 35(15_suppl). 11546–11546. 1 indexed citations

Jones, Robin L., Steven Attia, Cyrus R. Mehta, et al.. (2017). Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. Journal of Clinical Oncology. 35(15_suppl). TPS11081–TPS11081. 6 indexed citations

Attia, Steven, Kamalesh K. Sankhala, Richard F. Riedel, et al.. (2016). A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 34(15_suppl). 11016–11016. 16 indexed citations

Alvarez, Delia, Rebeca Fernandez‐Ruiz, & Lídia Sánchez-González. (2015). Stroke-based intelligent character recognition using a deterministic finite automaton. Logic Journal of IGPL. 23(3). 463–471. 6 indexed citations

10.

Gordon, Michael S., Francisco Robert, Daniela Matei, et al.. (2014). An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research. 20(23). 5918–5926. 61 indexed citations

11.

García, Agustin A., Vicky Makker, Daniel L. Spitz, et al.. (2014). Trc105 (Anti-Endoglin Antibody) in Combination with Bevacizumab (Bev) and As a Single Agent for Platinum Resistant Ovarian Cancer. Annals of Oncology. 25. iv310–iv310. 1 indexed citations

12.

Rosen, Lee S., Francisco Robert, Daniela Matei, et al.. (2013). A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 3059–3059. 3 indexed citations

13.

Rosen, Lee S., Herbert I. Hurwitz, Michael K. Wong, et al.. (2012). A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clinical Cancer Research. 18(17). 4820–4829. 148 indexed citations

14.

Gordon, Michael S., Herbert I. Hurwitz, Роберто Пили, et al.. (2011). A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3073–3073. 1 indexed citations

15.

Robert, Francisco, Michael Gordon, Lee S. Rosen, et al.. (2010). Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.. Journal of Clinical Oncology. 28(15_suppl). 3038–3038. 6 indexed citations

16.

Weiss, Glen J., Michael Gordon, Lee S. Rosen, et al.. (2010). Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.. Journal of Clinical Oncology. 28(15_suppl). 2576–2576. 4 indexed citations

17.

Gordon, Michael S., Glen J. Weiss, Lee S. Rosen, et al.. (2009). Abstract B62: A phase 1 study of oral TRC102 (methoxyamine), an inhibitor of base-excision repair, to potentiate the therapeutic effects of pemetrexed in patients with advanced refractory cancer. Molecular Cancer Therapeutics. 8(12_Supplement). B62–B62. 1 indexed citations

18.

Jones, M., et al.. (2008). Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. British Journal of Dermatology. 160(1). 127–131. 4 indexed citations

19.

Mota, Yailé Caballero, Delia Alvarez, Rafael Bello, & María M. García. (2007). Feature Selection Algorithms Using Rough Set Theory. 2 indexed citations

20.

Mota, Yailé Caballero, et al.. (2007). Feature Selection Algorithms Using Rough Set Theory. 407–411. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact